Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
19 February 2025 | Story Leonie Bolleurs | Photo Supplied
Prof Hagenmeier and Prof Jacobs
Prof Lynette Jacobs and Dr Cornelius Hagenmeier, one of her hosts at the Mittweida University of Applied Sciences (HSMW). Prof Jacobs, a visiting professor at this institution, had the opportunity to visit the HSMW on a guest scholarship grant from the State of Saxony.

Since its foundation in 1867, Mittweida University of Applied Sciences (HSMW) has had internationality as a trademark. In its early decades, more than half of its students came from abroad to study at this institution in Saxony, Germany. Today, the university is working with more than 100 partners worldwide, including the University of the Free State (UFS).

In September last year, the UFS signed a memorandum of understanding (MOU), outlining the intention to collaborate on the exchange of academic staff and researchers for teaching, lectures, and research, as well as for the sharing of expertise. Additionally, the institutions are also looking at student exchange opportunities, conducting joint research projects, hosting symposia, seminars, and conferences together, and exchanging academic information and materials.

Internationalisation as a cross-cutting process

Recently, Prof Lynette Jacobs, the interim Director of the Office for International Affairs at the UFS, visited the institution as a visiting professor at the HSMW, after receiving a guest professorship grant from the Free State of Saxony in Germany.

This opportunity not only provided her with the chance to gain insight into the HSMW and build an understanding of the possibilities for collaboration between the two institutions but also allowed her to directly contribute to their strategy development. She worked on a research project with her hosts, Prof Ramona Kusche, Dean of Studies, Global Communications in Business and Culture, and Dr Cornelius Hagenmeier, Head of Internationalisation. “We responded to the question of the extent to which the HSMW has achieved the goals of its 2018 internationalisation strategy,” she says.

In this study, they found that the HSMW is known for its attractive study programmes, forward-thinking content, interactive approaches, and its innovativeness and agility. This is reflected in the views of staff and students who participated in the interviews and the survey. It also became clear that the HSMW’s internationalisation strategy intentionally draws on the character and strengths of the university, which has enabling structures and appropriate governance frameworks for internationalisation. She says this research provided her with an opportunity to reflect on the UFS’ institutional strategic plans for internationalisation and how to strengthen the strategy and its implementation.

Internationalisation strategies in a different context

“The engagement with the HSMW provided me with an important additional perspective for the internationalisation strategy revision process at the UFS,” she states, adding that spending time at the HSMW gave her a unique understanding of the development and implementation of internationalisation strategies in a different context.

Besides reviewing the HSMW’s 2018 internationalisation strategy, Prof Jacobs has also collaborated on other research projects. She co-authored both a Routledge book chapter and a manuscript of a scientific article by Prof Kusche, Dr Hagenmeier, and others. As a result of the contacts she made during her visiting professorship, she is also now involved in the guest-editing of a special issue of the journal Internationalisation of Higher Education – Policy and Practice with the theme Institutional Internationalisation Strategies in a Rapidly Changing Global Environment.

Prof Jacobs delivered a number of guest lectures during her stay in Saxony, for instance, ‘Different ways of knowing, being and relating’ (to master’s students) and ‘South African culture, Ubuntu and Pan-Africanism’ (to undergraduate students).  She furthermore engaged in various dialogue sessions and workshops with lecturers and researchers at the HSMW, focusing on the integration of international and intercultural dimensions in curricula or in their research. She participated in discussions with some young female academics on science and career development and contributed to an international workshop on Institutional Internationalisation Strategies in a Rapidly Changing Global Environment, where initial research findings were presented that will inform the strategy's upcoming revision.

The young but growing partnership between the UFS and the HSMW promises benefits for both institutions. Two complementary face-to-face internationalisation colloquium sessions are scheduled for 2025:  the first during the HSMW International Week in June, and the second on the UFS Bloemfontein Campus in September.  This will further deepen the collaboration, building a shared understanding of integrated internationalisation, contributing to scholarship of internationalisation, and enriching the academic and cultural exchange between the universities. Collaboration in terms of mentorship programmes between the two universities is on the cards, while specific departments at the UFS (e.g. the Department of Social Work and the Department of Facilities) have already started their collaboration in 2024.

For more information about partnerships, contact the Office for International Affairs at partnerships@ufs.ac.za.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept